Previous 10 | Next 10 |
Entered into $100 Million Private Placement Agreement Finalized pivotal Phase 3 trial design for gedatolisib Received FDA Fast Track designation for gedatolisib in HR+/HER2- advanced breast cancer Management to host webcast and conference call today, May 16, 2022, at 4:30 p.m...
Celcuity (NASDAQ:CELC +6.6%) enters purchase agreement for common stock, preferred stock that may be convertible into common stock and warrants initially exercisable for preferred stock that is expected to result in aggregate proceeds of $100M. Company expects to use the net proceed...
Proceeds to Advance Clinical Development of Gedatolisib Including Forthcoming Phase 3 Clinical Study (VIKTORIA-1) MINNEAPOLIS, MN / ACCESSWIRE / May 16, 2022 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagn...
MINNEAPOLIS, MN / ACCESSWIRE / May 9, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating patients with cancer, today announced that it will release its financial results for the first qu...
The following slide deck was published by Celcuity Inc. in conjunction with this event. For further details see: Celcuity (CELC) Investor Presentation - Slideshow
MINNEAPOLIS, MN / ACCESSWIRE / April 5, 2022 / Celcuity Inc. (NASDAQ:CELC) , a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating patients with cancer, today announced that Brian Sullivan, Chairman, Chief Executive Officer,...
The following slide deck was published by Celcuity Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Celcuity Inc. 2021 Q4 - Results - Earnings Call Presentation
Celcuity, Inc. (CELC) Q4 2021 Earnings Conference Call March 23, 2022 4:30 PM ET Company Participants Robert Uhl – ICR Westwicke Brian Sullivan – Chief Executive Officer and Co-founder Vicky Hahne – Chief Financial Officer Igor Gorbatchevsky – Chief Medical Officer...
Celcuity press release (NASDAQ:CELC): Q4 Non-GAAP EPS of -$0.37 misses by $0.02. At December 31, 2021, Celcuity had cash and cash equivalents of $84.3 million, compared to cash and cash equivalents of $11.6 million at December 31, 2020. For further details see: Celcuity Non-GAAP EPS of ...
Finalized pivotal Phase 3 trial design following formal meetings with FDA Received FDA Fast Track designation for gedatolisib in HR+/HER2- metastatic breast cancer Presented updated Phase 1b data during a Spotlight Poster-Discussion Session at the 2021 San Antonio Breast Cancer Sy...
News, Short Squeeze, Breakout and More Instantly...
2024-07-10 10:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
MINNEAPOLIS, June 03, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the Jefferies Global Healthcare Conference to be held in New York on June 4-6, 2024. ...
2024-05-30 16:00:09 ET Bradley Canino from Stifel Nicolaus issued a price target of $40.00 for CELC on 2024-05-30 14:29:00. The adjusted price target was set to $40.00. At the time of the announcement, CELC was trading at $15.28. The overall price target consensus is at ...